이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

AstraZeneca 미래 성장

Future 기준 확인 4/6

AstraZeneca (는) 각각 연간 14.7% 및 6.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 15.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 31.3% 로 예상됩니다.

주요 정보

14.7%

수익 성장률

15.6%

EPS 성장률

Pharmaceuticals 수익 성장	14.3%
매출 성장률	6.1%
향후 자기자본 수익률	31.3%
애널리스트 커버리지	Good
마지막 업데이트	19 Jun 2024

최근 미래 성장 업데이트

Earnings Update: AstraZeneca PLC Beat Earnings And Now Analysts Have New Forecasts For This Year

Apr 27

Recent updates

These 4 Measures Indicate That AstraZeneca (LON:AZN) Is Using Debt Reasonably Well

Jun 05

Earnings Update: AstraZeneca PLC Beat Earnings And Now Analysts Have New Forecasts For This Year

Apr 27

AstraZeneca PLC's (LON:AZN) P/E Is On The Mark

Mar 30

수익 및 매출 성장 예측

LSE:AZN - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	58,787	11,635	13,724	16,115	21
12/31/2025	55,541	10,423	11,783	14,473	26
12/31/2024	51,656	8,761	8,661	11,666	26
3/31/2024	47,611	6,331	5,887	9,698	N/A
12/31/2023	45,811	5,955	6,858	10,345	N/A
9/30/2023	44,994	5,896	7,270	10,363	N/A
6/30/2023	44,485	6,163	6,854	10,179	N/A
3/31/2023	43,840	4,705	6,357	9,709	N/A
12/31/2022	44,351	3,288	7,684	9,808	N/A
9/30/2022	45,155	2,040	6,538	8,828	N/A
6/30/2022	44,038	-1,253	5,789	7,617	N/A
3/31/2022	41,487	-1,063	5,721	7,261	N/A
12/31/2021	37,417	112	4,350	5,963	N/A
9/30/2021	32,816	1,471	5,184	6,343	N/A
6/30/2021	29,528	3,771	5,421	6,446	N/A
3/31/2021	27,583	3,977	4,899	6,594	N/A
12/31/2020	26,617	3,196	3,144	4,799	N/A
9/30/2020	25,871	2,497	3,273	4,376	N/A
6/30/2020	25,699	2,148	3,057	3,657	N/A
3/31/2020	25,247	1,522	2,789	3,495	N/A
12/31/2019	24,384	1,335	2,585	2,969	N/A
9/30/2019	24,137	2,056	4,230	3,818	N/A
6/30/2019	23,071	2,188	3,543	3,184	N/A
3/31/2019	22,403	2,408	3,621	2,371	N/A
12/31/2018	22,090	2,155	3,585	2,618	N/A
9/30/2018	21,450	2,422	1,202	1,391	N/A
6/30/2018	22,342	2,677	2,854	3,165	N/A
3/31/2018	22,238	2,804	3,468	3,350	N/A
12/31/2017	22,465	3,001	N/A	3,578	N/A
9/30/2017	22,273	3,542	N/A	4,541	N/A
6/30/2017	21,740	3,870	N/A	3,109	N/A
3/31/2017	22,292	3,390	N/A	3,040	N/A
12/31/2016	23,002	3,499	N/A	4,145	N/A
9/30/2016	23,816	2,465	N/A	2,756	N/A
6/30/2016	24,062	2,221	N/A	3,690	N/A
3/31/2016	24,766	2,921	N/A	4,589	N/A
12/31/2015	24,708	2,825	N/A	3,324	N/A
9/30/2015	25,025	1,696	N/A	4,595	N/A
6/30/2015	25,689	1,180	N/A	4,800	N/A
3/31/2015	26,144	1,279	N/A	5,799	N/A
12/31/2014	26,547	1,233	N/A	7,058	N/A
9/30/2014	26,675	1,030	N/A	7,694	N/A
6/30/2014	26,316	2,022	N/A	6,862	N/A
3/31/2014	25,786	2,049	N/A	6,389	N/A
12/31/2013	25,806	2,556	N/A	7,400	N/A
9/30/2013	26,149	4,587	N/A	7,770	N/A
6/30/2013	26,581	4,852	N/A	7,961	N/A

애널리스트 미래 성장 예측

수입 대 저축률: AZN 의 연간 예상 수익 증가율( 14.7% )이 saving rate( 1.8% 보다 높습니다. ).

수익 vs 시장: AZN 의 연간 수익( 14.7% ) UK 시장( 12.6% 보다 빠르게 성장할 것으로 예상됩니다. 12.6% 연간).

고성장 수익: AZN 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: AZN 의 수익(연간 6.1% ) UK 시장( 3.5% 보다 빠르게 성장할 것으로 예상됩니다. 3.5% 연간).

고성장 수익: AZN 의 수익(연간 6.1% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: AZN 의 자본 수익률은 3년 내에 최고 수준이 될 것으로 예상됩니다. ( 31.3 %)

AstraZeneca 미래 성장

Future 기준 확인 4/6

주요 정보

최근 미래 성장 업데이트

Earnings Update: AstraZeneca PLC Beat Earnings And Now Analysts Have New Forecasts For This Year

AstraZeneca PLC Reiterates Earnings Guidance for the Year 2024

Recent updates

AstraZeneca plc Updates on the CAPItello-290 Phase III Trial for Truqap Plus Chemotherapy

AstraZeneca Announces CALQUENCE (Acalabrutinib) Plus Chemoimmunotherapy Reduced the Risk of Disease Progression or Death by 27% Vs. Standard of Care in Patients with Untreated Mantle Cell Lymphoma in Echo Phase III Trial

Daiichi Sankyo and AstraZeneca PLC Provides Positive Results from the DESTINY-Breast06 Phase 3 Trial

These 4 Measures Indicate That AstraZeneca (LON:AZN) Is Using Debt Reasonably Well

AstraZeneca's Tagrisso (Osimertinib) Announces the Addition of Pemetrexed and Platinum-Based Chemotherapy Recommended for Approval in the European Union for 1St-Line Treatment of Adult Patients

Daiichi Sankyo and AstraZeneca PLC Provides an update on TROPION-Lung01 Phase 3 Trial

AstraZeneca PLC Phase III Trial of Sipavibart Long-Acting Antibody Met Primary Endpoints in Preventing COVID-19 in Immunocompromised Patient Population

AstraZeneca PLC Announces Positive High-Level Results from an Interim Analysis of the Echo Phase III Trial

AstraZeneca PLC and Daiichi Sankyo Announces ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Improved PFS in HER2-Low and Ultralow

Earnings Update: AstraZeneca PLC Beat Earnings And Now Analysts Have New Forecasts For This Year

AstraZeneca PLC Reiterates Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Astrazeneca plc Announces IMFINZI (Durvalumab) Plus Chemotherapy Doubled Overall Survival Rate At Three Years for Patients with Advanced Biliary Tract Cancer in Topaz-1 Phase III Trial

AstraZeneca’s FASENRA Approves for Treatment of Children Aged 6 to 11 with Severe Asthma by the US Food and Drug Administration

AstraZeneca PLC Intends to Increase the Annualized Dividend for 2024

AstraZeneca PLC's Imfinzi Shows Significantly Improved Overall Survival and Progression-Free Survival for Patients with Limited-Stage Small Cell Lung Cancer in Adriatic Phase III Trial

Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

AstraZeneca PLC's (LON:AZN) P/E Is On The Mark

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견